The meticulously designed hemoperfusion adsorbent was synthesized employing one- step suspension polymerization, using harnessing styrene and divinylbenzene as constituent monomer and bridging agent. Critical to the process is the incorporation of 2- benzylacrylic acid and diethylaminoethyl methacrylate, which were strategically introduced to participate in the copolymerisation reaction. This was achieved through a methodical augmentation of the quantity and ratio of porogenic agent, a pivotal aspect of the synthesis. A thorough characterization of the intricate pore structure of adsorbent was conducted by N₂ adsorption- desorption analysis. This was followed by a series of in vitro adsorption experiments and blood compatibility trials. These were undertaken with the specific aim of evaluating the safety and efficacy of the newly developed adsorbent. The results, which are both comprehensive and illuminating, reveal that the adsorbent exhibits a specific surface area of 582 m²/g. This is accompanied by a considerable quantity of mesopores and an extensive microporous region. Remarkably, the adsorbent demonstrates superlative adsorption efficiency for an array of toxins, ranging from medium to macromolecular toxins, and even extending to protein-bound toxins. Additionally, it displays laudable haemocompatibility. Consequently, these findings underscore the potential of this adsorbent as an effective option for blood perfusion treatment in patients suffering from uremia.